We herein present a case study of a patient with heart failure with a preserved ejection fraction and severe symptoms who underwent interatrial shunt device implantation and follow-up at a tertiary care heart failure clinic. The interatrial shunt device implantation was successful. No adverse events occurred, and the device prevented hospitalization for heart failure during long-term follow-up.

Cardiology Fellow Department of Cardiology Na Homolce Hospital Cardiovascular Center Roentgenova 2 150 30 Prague 5 Czech Republic

Current affiliation Deputy Chief Department of Radiology 3rd Faculty of Medicine University Hospital Královské Vinohrady Charles University Šrobárova 50 100 34 Prague 10 Czech Republic

Director of Cardiac Arrhythmia Services for Mount Sinai Hospital and the Mount Sinai Health System Professor of Medicine in Cardiac Electrophysiology at Icahn School of Medicine at Mount Sinai 1468 Madison Avenue New York NY 10029 USA

Former affiliation Department of Radiology Na Homolce Hospital Roentgenova 2 150 30 Prague 5 Czech Republic

Head of CathLab Department of Cardiology Na Homolce Hospital Cardiovascular Center Roentgenova 2 150 30 Prague 5 Czech Republic

Head of Department of Cardiology Na Homolce Hospital Cardiovascular Center Roentgenova 2 150 30 Prague 5 Czech Republic

Head of Echocardiography Labs Department of Cardiology Na Homolce Hospital Cardiovascular Center Roentgenova 2 150 30 Prague 5 Czech Republic

Head of Heart Failure Clinic Department of Cardiology Na Homolce Hospital Cardiovascular Center Roentgenova 2 150 30 Prague 5 Czech Republic

Professor of Medicine Department of Internal Medicine University Hospital Královské Vinohrady 3rd School of Medicine Charles University Šrobárova 50 100 34 Prague 10 Czech Republic

Senior Vice President and Chief Medical Officer Corvia Medical Inc One Highwood Drive Suite 300 Tewksbury MA 01876 USA

Zobrazit více v PubMed

Hasenfuß G, Hayward C, Burkhoff D, et al.. REDUCE LAP-HF study investigators. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial. Lancet 2016; 387: 1298–1304. PubMed

Pocock SJ, Ariti CA, McMurray JJV, et al.. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J 2013; 34: 1404–1413. PubMed

Gagnier JJ, Kienle G, Altman DG, et al.; CARE Group. The CARE guidelines: consensus-based clinical case reporting guideline development. Headache 2013; 53: 1541–1547. PubMed

Søndergaard L, Reddy V, Kaye D, et al.. Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure. Eur J Heart Fail 2014; 16: 796–801. PubMed

Shah SJ, Feldman T, Ricciardi TM, et al.. One-year safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) trial: a randomized clinical trial. JAMA Cardiol 2018; 3: 968–977. PubMed PMC

REDUCE LAP-HF TRIAL II. https://clinicaltrials.gov/ct2/show/NCT03088033